Johnson & Johnson's long-running effort to put litigation claiming its talc products caused cancer has continued with a third attempt to place a subsidiary company into bankruptcy.
Johnson & Johnson's target of $5 billion in sales for its EGFRxMET bispecific antibody Rybrevant has moved a step closer, after a new FDA approval in non-small cell lung cancer (NSCLC).
Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encour
In a bid to put litigation over the safety of its talc products into the rearview mirror, Johnson & Johnson has added another $1.1 billion to its settlement offer, according to media re
Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete wit
Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US.